menu search

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Shareholder alert: the gross law firm notifies shareholders of view, inc. f/k/a cf finance acquisition corp. ii of a class action lawsuit and a lead plaintiff deadline of october 18, 2021 - (view)

New York, New York--(Newsfile Corp. - October 8, 2021) -  The securities litigation law firm of The Gross Law Firm issues the following notice on beh...

October 8, 2021, 8:03 pm

Shareholder alert: the gross law firm notifies shareholders of view, inc. f/k/a cf finance acquisition corp. ii of a class action lawsuit and a lead plaintiff deadline of october 18, 2021 - (view)

New York, New York--(Newsfile Corp. - October 8, 2021) -  The securities litigation law firm of The Gross Law Firm issues the following notice on beh...

October 8, 2021, 8:03 pm

Shareholder alert: the gross law firm notifies shareholders of view, inc. f/k/a cf finance acquisition corp. ii of a class action lawsuit and a lead plaintiff deadline of october 18, 2021 - (view)

New York, New York--(Newsfile Corp. - October 8, 2021) -  The securities litigation law firm of The Gross Law Firm issues the following notice on beh...

October 8, 2021, 8:03 pm

Shareholder alert: levi & korsinsky, llp notifies shareholders of view, inc. f/k/a cf finance acquisition corp. ii of a class action lawsuit and a lead plaintiff deadline of october 18, 2021 - view

New York, New York--(Newsfile Corp. - October 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities ...

October 8, 2021, 3:24 pm

Shareholder alert: levi & korsinsky, llp notifies shareholders of view, inc. f/k/a cf finance acquisition corp. ii of a class action lawsuit and a lead plaintiff deadline of october 18, 2021 - view

New York, New York--(Newsfile Corp. - October 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities ...

October 8, 2021, 3:24 pm

Shareholder alert: levi & korsinsky, llp notifies shareholders of view, inc. f/k/a cf finance acquisition corp. ii of a class action lawsuit and a lead plaintiff deadline of october 18, 2021 - view

New York, New York--(Newsfile Corp. - October 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities ...

October 8, 2021, 3:24 pm


Search within

Pages Search Results: